Musculoskeletal companies develop therapies, diagnostics and technologies for conditions affecting bones, joints, muscles, tendons and connective tissues. Their work supports pain management, tissue repair, mobility and the treatment of chronic and degenerative disease.
This category includes companies working on:
Browse 29 UK musculoskeletal companies below.
CSF-1R antibody therapy for tenosynovial giant cell tumour
SynOx Therapeutics is a late-stage biopharmaceutical company developing emactuzumab, a humanised monoclonal antibody targeting CSF-1R, for the treatment of tenosynovial giant cell tumour and other macrophage-driven conditions. Emactuzumab was licensed from Roche and inhibits the CSF-1 receptor to deplete…
Synthetic platform for precision delivery of biologics in tissue repair
Renovos Biologics is a biotech company developing precision delivery technologies for regenerative medicine, drawing on decades of academic research in skeletal stem cells, biomaterials and translational orthopaedic science at the University of Southampton. Its proprietary synthetic platform enables injectable,…
Stem cell therapies for equine musculoskeletal injuries
BioDivide Limited is a regenerative medicine company developing and commercialising stem cell therapies, with a current focus on equine musculoskeletal conditions. Its product uses a non-invasive proprietary method to collect and process stem cells from horses, delivering a standardised, frozen, ready-to-inject…
Silicon-based RNA delivery platform for rare disease therapeutics
SiSaf is a biopharmaceutical company developing RNA therapeutics using its proprietary platform, which combines bioabsorbable silicon with organic lipid materials to improve the stability, safety, and transfection efficiency of nucleic acid payloads. The platform addresses known limitations of conventional lipid…
Standardised mesenchymal stromal cell therapies for chronic tissue repair
TrophiCell develops cell therapies based on mesenchymal stromal cells, which release signals involved in tissue repair and immune regulation. Its patented production method aims to generate standardised cells at scale from a single donor, addressing variability associated with earlier cell therapy approaches. The…
AI-driven isoform sequencing platform for movement disorder and ageing research
Entelo Bio is an Oxford-based biotechnology company developing a proprietary single-cell isoform sequencing and AI platform to decode disease biology in conditions affecting human movement and ageing. Built on research from the University of Oxford's Botnar Institute for Musculoskeletal Sciences, the platform combines…
Lab-grown human muscle platform for preclinical drug testing and safety assessment
Myomaker Bio is a UK-based CRO specialising in pre-clinical muscle biology. The company has developed a platform of lab-grown human skeletal muscle tissues and organs that replicate the structure and function of native muscle, enabling researchers to study drug response, toxicity, injury and regeneration under…
Materials science testing and consultancy for life science product development
Lucideon is a materials development and testing organisation providing consultancy, characterisation, and analytical services to pharmaceutical, medical device, and biotechnology clients. Operating from ISO 17025 and GMP-accredited laboratories, the company supports product development from early-stage materials…
Clinical-stage company developing treatments for cancer cachexia and muscle wasting
Actimed Therapeutics is a clinical-stage specialty pharma developing treatments for cancer cachexia and muscle wasting disorders, areas with significant unmet need and no globally approved therapies. Its lead programme has completed Phase 1 and received FDA IND approval, with a Phase 2b/3 trial planned in non-small…